top of page
BOP2-Comb: Bayesian Optimal Phase II Design for Optimizing Doses and Assessing Contribution of Components in Drug Combinations
Date: August 19, 2025 PMID: 10.1007/s43441-025-00860-5 Category: N/A Authors: Xiaohan Chi, Ying Yuan, Ruitao Lin Abstract: 40830695 Background: Personalized cancer treatment using combination therapies offers substantial therapeutic benefits over single-agent treatments in most cancers. However, unmet clinical needs and increasing market competition pressure drug developers to quickly optimize combination doses and clearly demonstrate the contribution of each component when d
bgtaylor1
Nov 11, 20252 min read
bottom of page